RECORDATI AND LEESPHARM ANNOUNCE PARTNERSHIP FOR ZANIDIP® IN CHINA
2010-03-15 · Lee's Pharmaceutical Limited · original leespharm.com ↗
DISTRIBUTION AGREEMENT SIGNED BETWEEN THE COMPANIES FOR THE MARKETING OF “LERCANIDIPINE TABLETS” IN CHINA Milan and Hong Kong, March 15, 2010—Lee’s Pharmaceutical Holdings Limited (GEM Stock: 8221: Website: www.leespharm.com) today announced in conjunction with Recordati S.p.A. (RECI.MI, REC IM, ISIN IT0003828271. Website: www.recordati.com), a European pharmaceutical group, the execution of a License and Supply Agreement for Recordati’s original product, Zanidip® (lercanidipine), in China. The agreement grants Leespharm an exclusive license to market and sell, Zanidip® (lercanidipine tablets) for the treatment of hypertension in the People’s Republic of China.
The release as fetched from its publisher. leespharm.com ↗